AIM: To access the efficacy of chemotherapy plus radiofrequency ablation (RFA) as one line of treatment in inoperable colorectal liver metastases. METHODS: Eligible patients were included in three Phase II studies. In the first study percutaneous RFA was used first followed by 6 cycles of 5-fluorouracil, leucovorin and irinotecan combination (FOLFIRI) (adjunctive chemotherapy trial). In the other two, chemotherapy (FOLFIRI or 5-fluorouracil, leucovorin and oxaliplatin combination) up to 12 cycles was used first with percutaneous RFA offered to responding patients (primary chemotherapy trials). RESULTS: Thirteen patients were included in the adjunctive chemotherapy trial and 17 in the other two. At inclusion they had 1-4 liver metastases (up to 6.5 cm in size). Two patients died during chemotherapy. All patients in the adjunctive chemotherapy trial and 44% in the primary chemotherapy studies had their metastases ablated. Median PFS and overall survival in the adjunctive study were 13 and 24 mo respectively while in the primary chemotherapy studies they were 10 and 21 mo respectively. Eighty one percent of the patients had tumour relapse in at least one previously ablated lesion. CONCLUSION: Chemotherapy plus RFA in patients with low volume inoperable colorectal liver metastases seems safe and relatively effective. The high local recurrence rate is of concern.
AIM: To access the efficacy of chemotherapy plus radiofrequency ablation (RFA) as one line of treatment in inoperable colorectal liver metastases. METHODS: Eligible patients were included in three Phase II studies. In the first study percutaneous RFA was used first followed by 6 cycles of 5-fluorouracil, leucovorin and irinotecan combination (FOLFIRI) (adjunctive chemotherapy trial). In the other two, chemotherapy (FOLFIRI or 5-fluorouracil, leucovorin and oxaliplatin combination) up to 12 cycles was used first with percutaneous RFA offered to responding patients (primary chemotherapy trials). RESULTS: Thirteen patients were included in the adjunctive chemotherapy trial and 17 in the other two. At inclusion they had 1-4 liver metastases (up to 6.5 cm in size). Two patients died during chemotherapy. All patients in the adjunctive chemotherapy trial and 44% in the primary chemotherapy studies had their metastases ablated. Median PFS and overall survival in the adjunctive study were 13 and 24 mo respectively while in the primary chemotherapy studies they were 10 and 21 mo respectively. Eighty one percent of the patients had tumour relapse in at least one previously ablated lesion. CONCLUSION: Chemotherapy plus RFA in patients with low volume inoperable colorectal liver metastases seems safe and relatively effective. The high local recurrence rate is of concern.
Authors: T de Baere; D Elias; C Dromain; M G Din; V Kuoch; M Ducreux; V Boige; N Lassau; V Marteau; P Lasser; A Roche Journal: AJR Am J Roentgenol Date: 2000-12 Impact factor: 3.959
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: L Solbiati; T Livraghi; S N Goldberg; T Ierace; F Meloni; M Dellanoce; L Cova; E F Halpern; G S Gazelle Journal: Radiology Date: 2001-10 Impact factor: 11.105
Authors: Gunnar Folprecht; Matthew T Seymour; Leonard Saltz; Jean-Yves Douillard; Hartmut Hecker; Richard J Stephens; Timothy S Maughan; Eric Van Cutsem; Philippe Rougier; Emmanuel Mitry; Ute Schubert; Claus-Henning Köhne Journal: J Clin Oncol Date: 2008-03-20 Impact factor: 44.544
Authors: T J White; S H Roy-Choudhury; D J Breen; J Cast; A Maraveyas; E F Smyth; J E Hartley; J R T Monson Journal: Dig Surg Date: 2004-09-13 Impact factor: 2.588
Authors: Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens Journal: Lancet Date: 2007-07-14 Impact factor: 79.321
Authors: Thomas J Vogl; Parviz Farshid; Nagy N N Naguib; Abbas Darvishi; Babak Bazrafshan; Emmanuel Mbalisike; Thorsten Burkhard; Stephan Zangos Journal: Radiol Med Date: 2014-06-04 Impact factor: 3.469
Authors: Klaas M Govaert; Charlotte S van Kessel; Martijn Lolkema; Theo J M Ruers; Inne H M Borel Rinkes Journal: Curr Colorectal Cancer Rep Date: 2012-03-17